SBIR/STTR Research Award
Developing therapeutic antibodies for Alzheimer's disease
Award amount
$498,534Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VERSAPEUTICS INC
- Proposal award date
- 2022-08-01
- Contract end date
- 2023-07-31
- UEI
- EGSGJKXHKBN5
- Solicitation number
- PA21-259
- Topic code
- NIA
Research abstract
PROJECT SUMMARY/ABSTRACTMillions of Americans suffer from Alzheimer’s disease and there are currently no therapies available to
prevent or slow the progression of the disease. The unmet medical needs of individuals with Alzheimer’s disease
result in hundreds of billions of dollars of costs in paid and unpaid caregiving in the United States every year.
VersaPeutics is a small business developing novel therapeutics for Alzheimer’s disease. In this Phase I SBIR
project we will perform preclinical studies to determine the feasibility of antibody-based therapeutics that are
designed to treat Alzheimer’s disease using a unique mechanism of action, by examining pharmacokinetics,
efficacy, toxicity and toxicokinetic. At the conclusion of these studies, we will have met several important
milestones that will support further preclinical development of our novel therapeutics for Alzheimer’s disease.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical Toxicology Study of Intrathecal VersaMab-101 for spinal cord injury treatment
- Toxicology and Efficacy Studies of Intrathecal VersaMab-101 for spinal cord injury treatment
- Developing therapeutic antibodies for Alzheimer's disease
- Pharmacokinetics and efficacy of intrathecal VersaMab-101 delivery foracute spinal cord injury
- Preclinical Development of VERSAMAB-101 for Spinal Cord Injury
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
- A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
- VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care
- Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias
- Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
Research funding history
6 SBIR/STTR records share this UEI (2021–2024). Reported award amounts total $7,005,930. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services